Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3323-3328

  Niu, Jiaxin ^a   Andres, Grant ^a   Kramer, Kim ^b   Kundranda, Madappa N ^c   Alvarez, Ricardo H ^d   Klimant, Eiko ^e   Parikh, Ankur R ^e   Tan, Bradford ^f   Staren, Edgar D ^g   Markman, Maurie ^h  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b CTCACA Medicine and Science   (United States)

^c Banner MD Anderson Cancer Center   (United States)

^d Southeastern Regional Medical Center at CTCA   (United States)

^e Department of Medical Oncology   (United States)

^f CTCA at Midwestern Regional Medical Center   (United States)

^g Advanced Individual Medicine   (United States)

^h CTCA Medicine and Science   (United States)

Author keywords

Breast cancer; Endocrine therapy; ESR1 mutation; Genomic alteration; Next generation sequencing; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; EXEMESTANE; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE DURATION; DISTANT METASTASIS; DRUG EFFECT; ESR1 GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING;

EID: 84947064101     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S92443     Document Type: Article

References (21)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmeno­pausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–3767.
3. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letro­zole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–2109.
4. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res. 2004;10(23):7972–7977.
5. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized pla­cebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–1670.
6. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600.
7. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: ful­vestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337.
8. Arpino G, De Angelis C, Giuliano M, et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology. 2009;77 Suppl 1:23–37.
9. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or with­out entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–2135.
10. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
11. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
12. Jordan VC, Curpan R, Maximov PY. Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. J Natl Cancer Inst. 2015;107(6):djv075.
13. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446–1451.
14. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439–1445.
15. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87(6):446–451.
16. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and vali­dation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
17. Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57(7):1244–1249.
18. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
19. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of con­stitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20(7):1757–1767.
20. Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17(3):279–288.
21. Turner NC, Ro J, Andre F, et al. PALOMA3: a double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol. 2015;33 abstr LBA502.